Electra Therapeutics is focused on developing innovative therapies for immunological diseases and cancer by targeting Signal Regulatory Proteins (SIRP). Their portfolio includes SIRP-directed antibodies that operate through a unique mechanism of action, which has the potential to address the underlying pathologies of a wide range of diseases. The company emphasizes a rigorous scientific approach to explore and validate novel therapeutic targets, aiming to meet critical unmet medical needs and empower patients with breakthrough treatments.

The company's pipeline is characterized by first-in-class programs that are internally generated, indicating a strong commitment to innovation. Each program represents an opportunity to make a significant impact on diseases with high unmet needs, such as secondary hemophagocytic lymphohistiocytosis (sHLH), T cell lymphoma (TCL), and T cell acute lymphoblastic leukemia (T-ALL). Electra Therapeutics is dedicated to advancing these programs, with a focus on proof-of-concept and investigational new drug development, showcasing their commitment to transforming patient care through novel therapeutic solutions.

United States

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Electra Therapeutics

Company Details